Application to Drug Substance Crystallization Marino Nebuloni

Similar documents
Quality by Design nella cristallizzazione degli API

Pat Monitoring of Particles in API Manufacture and Formulation

Dr Thomas McGlone. Optimisation of Industrial Crystallisation Processes: Case Studies from the CMAC Future Manufacturing Research Hub

Strategic Implantation of PAT : FDA Perspective

Nucleation & Growth Kinetics: A Comparison of FBRM and Laser Diffraction

냉각결정화기술의응용전략 -2 고려대화공생명공학과양대륙

Continuous Crystallization of Pharmaceuticals. Allan S. Myerson

Insight into solid state properties during processing

White Paper. Crystallization in Process Chemistry Applying Simple PAT Tools. Author: Des O'Grady PhD, METTLER TOLEDO

Developing Pharmaceutical Continuous Crystallization Processes - Knowledge & Gaps. Chris Price on behalf of the IMI team Product Development

Dr Claire MacDonald Business Development Manager CMAC National Facility

Agilent TRS100 Raman. Quantitative Pharmaceutical Analysis System

Process Analytical Technology Applications in Crystallisation Development

Loughborough University Institutional Repository. This item was submitted to Loughborough University's Institutional Repository by the/an author.

Regulatory Assessment

Controlled Crystallization of Salts from Nuclear Waste Solutions 15235

Solubility Curve and Metastable zone Width using Lasentec FBRM & PVM

CMAC: A National Research Centre in Continuous Manufacturing and Crystallisation

Continuous Crystallisation and Manufacture

ICH Q8/Q8(R)

Batch Statistical Process Control (BSPC): a powerful multi-level risk & process analytics tool

Siemens AG All rights reserved.

PQLI Engineering Controls and Automation Strategy

ABOUT LOUGHBOROUGH UNIVERSITY CHEMICAL ENGINEERING RESEARCH ASSOCIATE CONTINUOUS CRYSTALLISATION AND MANUFACTURING REQ15805 OCTOBER 2015

PAT and Quality by Design exemplified in a Mock P2 submission for examplain tablets. Part 1: Concept and Principles Part 2: Mock P2 Submission

Taking mechanistic models from R&D and Engineering into Operations

Continuous Manufacturing

Polymorph Screening Technology by Controlling Crystallization

Scientific Considerations for Continuous API Manufacturing

Polymorph Screening Strategies and a Concomitant Polymorph Case Study

Application of Quality by Design (QbD) in product development. James E. Polli September 16, 2015

Maximizing efficiency: Process Analytical Technologies and Process Intensification

PLEASE SCROLL DOWN FOR ARTICLE

Water in Food, Lausanne 2004

Small Molecule Crystallization

Inline Monitoring to Improve Purification of Biological Systems

Process analytical technology based approaches for the monitoring and control of size and polymorphic form in pharmaceutical crystallisation processes

PQLI Control Strategy Model and Concepts

Application Note. Introduction. Analysis of crystal polymorphism by Raman Spectroscopy for Medicine Development

CHALLENGES & OPPORTUNITIES OF ICHQ8 (PHARMACEUTICAL DEVELOPMENT) AN INDUSTRY PERSPECTIVE

Crystal Growth from Melts

White Paper. Advanced Strategies to Control Crystal Size Distribution. Author: Des O Grady PhD, METTLER TOLEDO

Amorphous Quantitation Strategy for Crystalline Drug Substance a GSK Perspective. Peter Varlashkin GSK, Durham, NC, USA PPXRD 11

A Study on Crystallization of Oxalic Acid in Batch Cooling Crystallizer

Quality by Design Considerations for Analytical Procedures and Process Control

On-line Monitoring of the Spherical Crystallization of Salicylic Acid. Omar S. Hasan 1 Helen M. Buettner 1 San Kiang 2

Application Note. Raman Spectroscopy Analysis of Crystalline Polymorphs for Pharmaceutical Development

NIRS, PAT, RTR testing EU experience and regulatory perspective

The Move to 100% Testing of Incoming Raw Material. Ravi Kalyanaraman, Ph.D. Global Analytical Technology Bristol-Myers Squibb

The use of surrogates for dissolution testing for Immediate Release (IR) formulations, when is it feasible?

VERISEQ NUCLEATION BETTER CONTROL OF NUCLEATION IN LYOPHILIZATION

Physical characterization and in vitro cytotoxicity screening of single-walled carbon nanotubes (SWNTs)

A.1 Physical and Chemical Properties of Model Systems

Development of Continuous Crystallisation Processes for Consistent Crystal Products

PHEN 612 SPRING 2008 WEEK 13 LAURENT SIMON

How the European Pharmacopoeia Provides the Framework to Implement QbD Principles

Applying QbD to Bioprocesses

Continuous Manufacture: Real-time Multivariate process monitoring

THE EFFECT OF MIXING ON THE METASTABLE ZONE WIDTH AND NUCLEATION KINETICS IN THE ANTI-SOLVENT CRYSTALLIZATION OF BENZOIC ACID

Crystallization Methods and Protein Crystal Properties. (adapted from )

Thermo Scientific ARL EQUINOX 100. X-ray Diffractometers

Identification of CPPs based on CQAs & Mechanistic Process & Product Understanding: A Case Study

Approval Application Form for Sakura Bloom Tablets

PAT - Seen from an Automation and Information Solutions Provider

Spectroscopy Fiber Optic Probes for In-line Analytical Analysis

Validation of Pharmaceutical Manufacturing Process Focus: APIs.

Investigating Differences in Solubility Between Crystalline and Amorphous Forms of Pharmaceuticals

Mitigating Commercial Risks in Continuous Manufacturing Drug Product

Studying Amorphous Pharmaceutical Materials by Powder X-Ray Diffraction and other Solid-State Techniques

QbD (Quality by Design) Has industry benefited from this? WHITE PAPER.

Optical microscopy Theoretical background Galina Kubyshkina

Lessons Learned in Tech Transferring a QbD/PAT enabled process

Needs and Opportunities for Continuous Manufacturing (industrial perspective)

Characterization of Li 3+ /Mg SO 4.7H 2 O Crystal

Regulatory Consideration for the Characterization of HOS in Biotechnology Products

Preliminary Studies on In Situ Monitoring of Lactose Crystallization Using Focused Beam Reflectance Measurement

COPYRIGHTED MATERIAL. Introduction to Crystallization Issues. Chapter 1

Implementation of a Multi-product Process Intensified Plant

VERISEQ nucleation. Improved lyophilisation through controlled nucleation.

Manufacturing Considerations for Liposomal Drug Products. Nanotechnology Workshop January 2014

COMPARISON OF SEMICONTINUOUS AND BATCH PRECIPITATION OF CALCIUM CARBONATE

PAT for the On-line Characterization of Continuous Manufacturing Systems

Particle Size Method Development and Validation in Support of NanoCrystal Colloidal Dispersion Formulation Characterization

Batch Reactor Temperature Control Improvement

Selective Crystallization of Metastable α-form of L- glutamic Acid through Feedback Concentration Control. Introduction

New generation of industrial crystallizers. Numerical simulation of a bubble growth induced by laser MOHAMMAD GHEISI

PAT Initiative Pilot Project API Production. Gerhard Korb. Sanofi-Aventis Deutschland GmbH. Process Development Chemistry

The Raman effect, discovered in 1928 by C.V. Raman in his

Pharmaceutical Manufacturing Technology Centre

3. STATE OF ART AND OBJECTIVES OF THESIS

How to Identify Critical Quality Attributes and Critical Process Parameters

LiquiSonic. SensoTech. Biotech applications. Protein and agent crystallization. Fermentor and filter control

Thermo Scientific ARL EQUINOX X-ray Diffractometers

Chapter 4: Recrystallization & Melting Point

Achieving Quality Beyond Compliance Through Continuous Manufacturing

MOISTURE CONTENT MEASUREMENT CASE STUDY

OVERVIEW OVERVIEW. At Particle Sciences, We Deliver, taking your API from concept to clinic. Contact us at to see how we can help.

Integrating OSIsoft PI System with syntq for High Performance, Low Maintenance PAT Method Integration

Scientific and Regulatory Considerations for Implementing Mathematical Models in the Quality by Design (QbD) Framework

Role of QOS in PMDA Review Process

Transcription:

Application to Drug Substance Crystallization Marino Nebuloni REDOX Monza Parma University

Objectives of the presentation 1.Crystallization principles 2.What are QbD (Quality by Designe) and PAT (Process Analytical Technique)? 3.Analytical Techniques for PAT Application 4.Examples of PAT in Crystallization of API 5.Summary

Crystallization Processes 1 Crystallization is a core technology of many sectors in the chemical process and allied industries 2 Involves a variety of business sectors, e.g..agrochemicals, catalysts, dyes/pigments, electronics, food/confectionery, health products, nano-materials, nuclear fuel, personal products & pharmaceuticals 3 Processes can involve complex process chemistry together with non-ideal reactor hydrodynamics.hence can be difficult to understand and scale-up from laboratory to production scale operation 4 Crystallization also forms part of a wider process system

Crystallization Process Systems

CRYSTAL CHARACTERISTICS

Phase Equilibria Understanding phase equilibria is crucial to crystallizer operation Solubility-supersolubility diagram

Supersaturation Supersaturation, c, is sometimes called the concentration driving force

Crystallization Kinetics particle formation processes depend upon supersaturation

Process Analytical Technology (PAT) in the assessment and control the Critical Variables in Crystallization Processes

The application of PAT to the crystallization means understand IDENTIFICATION MEASUREMENT PAT PREDICTION

Scientific Contributions for the application of the PAT Analytical Sensor Quality and Hazard design PAT Process Control Data Data Analysis Analysis

Fundamental Approach in Development Traditional Approach Causal Links Predict Performance Quality by Design Scale Up Prediction Real Time Control for Continuous Improvement Decision Based On Univariate Approach Data Derived From Trial & Error Experimentation Modeling for Mechanistic Understanding DOE (Multivariate Systems Approach) Identification of PCCP* PAT PCCP* Process Critical Control Parameter

Impact of On-line Process Analyzers - Crystallization - PAT Raw Material Reaction Purification Crystallization Isolation & Drying API Quality/Productivity Mechanistic & kinetic knowledge Parametric boundary Access to extreme conditions Real time monitoring & control Continuous quality assurance

Application for On-line Process Monitoring - Crystallization - SOLID STATE Physical properties intrinsic external Reaction Calorimetry FT-IR/ATR spectroscopy Raman Spectroscopy FBRM -Focuse BeamReflectance Measurements

Instrument characteristic requirements for on-line process monitoring

Analytical Techniques available on Spectroscopic Techniques the market NIR FT-IR/ATR Raman Light Scattering (laser) Mass-Spectrometry X-ray (Diffraction & Fluorescence) Turbidimetric and Rifractometric Techniques Turbidimetry Densitometry rifractometry Particles physical and morphologic properties Particle Size (FBRM) Photoacustic Etc.

Measurement technology review

REVIEW

Polymorphism and Particle Size modification during a crystallization process controlled by RC1, FT- IR/ATR and FBRM During a crystallization process of an API was observed : at the first step after seeding : * crystals with large Particle Size and polymorphic Form I at the second step (cooling phase): * Increase of small crystals instead of growth and transformation of the solid into polymorphic Form II

First Step : Lab Scale FT-IR/ATR & FBRM (Lasentec) into RC1 calorimeter FT-- IR/ATR FBRM RC1

Crystallization Heat of API recorded by RC1 seeding ---- Form I --------- Form I I --- Heat developed on the crystallization 5 40 4 Reactor Temperature 35 30 3 2 Conversion 25 20 1 0 Heat Flow 15 10 5-1 50 100 150 200 250 300 0 time (min)

N Totale N Conteggi di Particelle 45000 450 40000 400 35000 350 30000 300 25000 250 20000 200 15000 150 10000 100 5000 50 0 Esempio I Valore medio Crystallization Mean Diameter Profile and and Particles distribution count of byparticles FBRM Mean diameter DIAMETRO MEDIO Seeds Seeds (1) (1) (2) (2) (3) (3) Tr=36-->19 C 50 100 150 200 250 300 350 0 Time (min) 50 100 150 200 250 300 350 (4) (4) N Particles Maximum Growth Rate Time (min) 50 um 250 um Tr=36-->19 C (5) (5) 40 40 35 35 30 30 25 25 20 20 15 15 10 10 5 5 0 0 Diametro Diametro Medio Medio (um) (um)

Esempio I FT-IR Polymorphic Form modification during the crystallization controlled by FT-IR/ATR 45000 0.5 40000 (2) N Particles 0.45 N Totale di Particelle 35000 30000 25000 20000 15000 Form I (initial) (1) (3) (4) Tr=36-->19 C Form II (Final) 0.4 0.35 0.3 0.25 0.2 0.15 Concentrazione Relativa 10000 Seeds (5) 0.1 0.05 5000 0 0 50 100 150 200 250 300 350 Time (min) -0.05

Second Step: lab-max & mini plant

Reaction Calorimetry RC1 profiles Heat developed on the crystallization 5 40 4 Reactor Temperature 35 30 With only one solvent (standard process) 3 Conversion 2 1 Heat Flow 0-1 50 100 150 200 250 300 time (min) 25 20 15 10 5 0 Seeds addition Crystallization induced by the cosolvent Modify method (with co-solvent) 18 16 14 12 10 8 6 Heat flow Conversion 1.2 1 0.8 0.6 0.4 4 0.2 2 0 0-2 100 120 140 160 180 200 220 240 260 280 time (min) -0.2

Third Step: production scale

On-line Control of crystallization of polymorphic forms and Particle Size by FBRM (Lasentec) Active Principle (API) can exist into two polymorphic forms Form I - m.p = 222 C By slow cooling Form II - m.p = 219 C By rapid cooling

FBRM (Focused Beam Reflectance Measurement) Probe scheme nicr CSDIR c1ir TuIR c2ir TICR TICR Batch Cooling Crystallizer: Experimental Set-Up c1ir: Concentration Measurement 1 (Oscillating U-Tube Measurement) c2ir: Concentration Measurement 2 (Ultrasound Velocity Measurement) TuIR: Turbidometer (Backscatter Measurement) CSDIR: Crystal size Distribution Measurement (Chord Length Measurement FBRM) jacketed crystallizer

Particle Size distribution by FBRM during the cooling steps Cooling step from 90 to 55 C Particle Size distribution on the time at 55 C

Final Particle Size distribution in relation to the process temperature

FBRM application for monitoring an API crystallization process influenced by ph, concentration, Temperature and Induction time

Critical Quality Paramiters Concentration ph Solid state FBRM on line Filtrability Induction Time

Information collected on the time during the crystallization

Time 0 time Nucleation Growing Induction Time

Laboratory Scale-up Production F.B.R.M. F.B.R.M. Definition of CQa Quality Control P.A.T. Optimization

Experimental Data 8000 30000 N particelle 7000 6000 5000 4000 3000 Particelle 1-3 um Particelle 3-5 um Particelle 5-10 um Particelle 10-21 um Particelle 23-50 um Particelle 54-100 um N totale di particelle 25000 20000 15000 10000 2000 1000 Inizio 2h 5000 0 0 0.00.00 2.24.00 4.48.00 7.12.00 9.36.00 12.00.00 14.24.00 16.48.00 19.12.00 Tempo (h)

ph= 6.7 concentration : A mg/ml Poor filtrability Design Of Experiment Filtrazione F 7 A F 7 B F 6.7 A F 6.7 B NO F 7 A ph NO F 7 B NO F 6.7 A NO F 6.7 B Concentrazione

6000 25000 5000 4000 1-2 um 3-5 um 5-10 um 10-21 um 21-50 um 54-100 um N totale particelle 20000 N particelle 3000 15000 10000 N particelle totali 2000 1000 Inizio 3h 5000 0 0 0.00.00 2.24.00 4.48.00 7.12.00 9.36.00 12.00.00 14.24.00 16.48.00 19.12.00 tempo (h)

Final Result Filtrability F 7 A F 7 B 3 h F 6.7 A 2 h F 6.7 B NO F 7 A ph NO F 7 B 0.5 h NO F 6.7 A 0 h NO F 6.7 B Concentration Time

Impact of Agitation on Particle Size Distribution

Effect of Agitated Drying

Monitoring in Tumble Dryer

Continuous Crystallization controlled by PAT AIMS 1. To deliver consistent crystal quality (morphology, size and size distribution), not achieved consistently in large batch operations. 1. To investigate additional manufacturing advantages of COBC for crystallisation in continuous or semicontinuous modes 1. Improved filterability; 1. Reduced crystallisation time, space usage and utility and energy consumption; 1. Provision of seeding along the flow path.

Continuous Oscillatory Baffled Crystalliser Courteously by Jon-Paul Sherlock, AstraZeneca Continuous Material moves continuously through Oscillatory Although there is a net flow through the unit, the local flow moves back and forth Baffled. Reactor Small baffles are installed along the length to promote turbulence and hence mixing Or crystalliser, or extractor, or

How is mixing achieved? Mixing Mechanism Mixing controlled by oscillation Plug flow at relatively low flows Each cell is a CTSR Handles particulates

material moves through the crystalliser

Well controlled cooling rate

Product performance

Summary Advantage of PAT application i) Understanding of the uncertainties of the process; ii) Identification and quantification of the failure mechanisms on the crystallization process iii) Estimation of the risks associated with each step of the process. iv) Documentation of physical characteristics for the Regulatory Requirements

Thank you for your attention! Marino Nebuloni Parma University